<DOC>
	<DOCNO>NCT00082433</DOCNO>
	<brief_summary>The purpose clinical research study learn BMS-247550 add approve therapy capecitabine ( Xeloda ) provide measurable clinical benefit capecitabine alone woman metastatic breast cancer . Patients previously receive anthracycline taxane . The safety treatment also study .</brief_summary>
	<brief_title>Epothilone ( Ixabepilone ) Plus Capecitabine Versus Capecitabine Alone Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Patients must receive prior treatment include anthracycline ( i.e. , doxorubicin epirubicin ) taxane ( i.e. , paclitaxel docetaxel ) . Patients must receive two prior chemotherapy regimen . Patients receive treatment metastatic disease must relapse within one year . Patients may history brain and/or leptomeningeal metastasis . Patients may Grade 2 bad neuropathy time study entry . Patients may prior treatment epothilones and/or capecitabine ( i.e . Xeloda )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>